Search
Lamotrigine
go.drugbank.com/drugs/DB00555ApprovedInvestigationalLamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries. … While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850]
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesAmbrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalAmbrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. … It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening.
Categories: Antihypertensives for Pulmonary Arterial HypertensionVestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalVestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients. … Vestronidase alfa is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome, which is an inherited, rare genetic metabolic condition that
Sebelipase alfa
go.drugbank.com/drugs/DB11563ApprovedInvestigational[L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency. … The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawnIn the EMA, by 2015 it was under pharmacovigilance studies for the potential treatment of acute renal failure.[L1314]
Lepirudin
go.drugbank.com/drugs/DB00001ApprovedWithdrawn[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine
Palifermin
go.drugbank.com/drugs/DB00039ApprovedInvestigationalPalifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Categories: Detoxifying Agents for Antineoplastic TreatmentOpicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigational[L2336] Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. … Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.
Leniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45753] Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.[A258468] … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational[A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … [A189165] JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy